Parkinson disease: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• SNCA 10
• LRRK2 7
• NRF2 1
• GBA1 13
• NLRP3 1
• PINK1 1
• AKT 0
• PI3K 0
• GLP-1 0
• STING 0
• BDNF 1
• mTOR 0
• SIRT1 0
• TLR4 0
• PPAR 0
• AMPK 1
• TP53 0
• GPX4 0
• MAPK 0
• MAPT 0
• TNF 0
• APOE 1
• HMGB1 0
• JNK 0
• ERK 0
• HSP90 1
• JAK 0
• STAT3 0
• TREM2 0
• HDAC 0
• TDP-43 1
• NMDA 0
• TFEB 0
• HIF-1 1
• IL-1 0
• PARP 0
• CTNNB1 0
• GIP 0
• IL-17 0
• PCSK9 0
• ACE2 0
• AQP4 0
• BCL-2 0
• CSF1R 0
• FTO 0
• PKM2 0
• SGLT2 0
• CD38 0
• COX-2 0
• DPP-4 0
• G6PD 0
• IDO1 0
• PDE4 0
• PTEN 0
• YAP 0
• ALK 0
• APP 0
• ATM 0
• BACE1 0
• C9orf72 0

EU-13 is a filter, not a ranking: it only narrows the list.

1 of 1+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Trials whose registry record says individual participant data (IPD) will be shared.

No trial in this view states that it shares participant data.

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 23
• Organoids 19
• Mendelian Randomization Analysis 66
• CRISPR-Cas Systems 15
• Gene Expression Profiling 76
• Sequence Analysis, RNA 7
• Whole Genome Sequencing 7
• Exome Sequencing 12
• Proteomics 70
• Metabolomics 35
• Mass Spectrometry 12
• Flow Cytometry 4
• Immunohistochemistry 50
• Liquid Biopsy 3
• Xenograft Model Antitumor Assays 1
• Positron-Emission Tomography 103
• Magnetic Resonance Imaging 369
• Machine Learning 141
• Deep Learning 72
• Cohort Studies 185
• Genome-Wide Association Study 83

• Nanoplasmonic Aptasensing Enables Real-Time Optical Monitoring of Neurotransmitters in Living Brainstem Organoids.

  ACS Nano, Sept 2026

• Human iPSC-Derived Brain Cells, Organoids, and Organoids-on-Chips: Advancing Neurological Disease Modeling to Improve Clinical Outcome.

  Cells, Sept 2026

• Generation of Vascular Organoids from Human iPSCs to Study Neurodegenerative Processes.

  Bull Exp Biol Med, Sept 2026

• Midbrain organoids as next-generation models for Parkinson's disease: From pathogenesis to therapeutic discovery.

  Exp Neurol, Sept 2026

• Brain organoids in Parkinson's disease drug development: Human-specific models for translational discovery.

  Drug Discov Today, Jul 2026

• Air-Liquid interface midbrain organoids model the pathological features of Parkinson's disease.

  Neuroscience, Jul 2026

• Engineering functional ventral midbrain dopaminergic neurons in human organoids through WNT modulation and bioreactor culture.

  Mol Psychiatry, Jun 2026

• Development of Metabolic Stress in Vascular Organoids under Normal Conditions and with AD/PD-Associated Genetic Backgrounds.

  Biochemistry (Mosc), Jun 2026

• iPSC-Derived 3D Brain Organoids as Next-generation Platforms to Study Viral and Toxicant-associated Neurodegeneration.

  Stem Cell Rev Rep, May 2026

• SARS-CoV-2 Infection Induces Dopaminergic Neuronal Loss in Midbrain Organoids.

  J Neurochem, May 2026

See which targets of this disease your abstract mentions, and go to the people working on them.